Ophthalmic medical device company Sight Sciences today announced the launch of a new pivotal trial exploring the safety and effectiveness of its TearCare system in patients with dry eye disease. The Menlo Park, Calif.-based company’s TearCare system is a wearable therapeutic eyelid technology designed to deliver energy over a specified period to liquify meibum, an oily coating […]
Sight Sciences
Zimmer Biomet picks ex-Covidien exec Lannum for IR chief | Personnel Moves – March 20, 2018
Zimmer Biomet (NYSE:ZBH) said yesterday it tapped former Covidien investor relations head Coleman Lannum as its investor relations senior VP, reporting directly to prez & CEO Bryan Hanson. Lannum has more than 15 years in investor relations, having held positions with Mallinckrodt Pharmaceuticals (NYSE:MNK), Covidien and Tyco Healthcare. During his time with Covidien, Lannum oversaw the company’s initial […]
Sight Sciences raises $10m in Series C
Ophthalmic medical device company Sight Sciences said this week it closed a $10 million oversubscribed Series C round to support expanding manufacturing and its US commercial team and the launch of its devices into the dry eye and microinvasive surgery markets. The round was led by Allegro Investment Fund and was joined with full participation from existing […]
7 medtech stories we missed this week: April 14, 2017
From FDA approvals to business expansion plans, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. BioTelemetry launches offer to acquire LifeWatch BioTelemetry and LifeWatch announced in an April 9 press release that the 2 companies have entered a transaction agreement that states BioTelemetry will launch a tender offer […]
Terumo taps DeRyke for CEO | Personnel Moves | April 7, 2017
Terumo Corp. (TYO:4543) said yesterday it tapped Rob DeRyke as its new CV group prez & CEO, effective April 1, 2017, succeeding a retiring Mark Sutter. Prior to his appointment, DeRyke operated as Terumo CV group electromechanical systems division prez, the company said. “Under his leadership, Rob brought stability and improved profitability to the business,” Terumo […]
Sight Sciences wins Health Canada nod for TRAB 360
Venture-backed ophthalmic medical device company Sight Sciences said last week it won Health Canada approval for its TRAB 360 trabeculotomy system. The TRAB 360 system is now cleared for the microcatheterization of the Schlemm’s canal and cutting of trabecular meshwork to lower intraocular pressure in open angle glaucoma patients, the Menlo Park, Calif.-based company said. “My […]
Sight Sciences wins IDE for Visco 360
Venture-backed ophthalmic medical device company Sight Sciences said today it won FDA investigational device exemption approval to initiate a clinical trial of its Visco 360 Viscosurgical System for treating patients with glaucoma. The multi-center, randomized trial will compare ab interno canaloplasty with the Visco 360 system against selective laster trabeculoplasty. The study will investigate the […]
Sight Sciences brings in $7m Series B
Venture-backed ophthalmic medical device company Sight Sciences said today it closed an oversubscribed $7 million Series B round of financing. Sight Sciences produces the Trab 360 and Visco 360 surgical devices as well as a portfolio of technologies in the advanced stages of development for treating evaporative dry eye. The round was led by Dallas-based […]